Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
February 14, 2024 08:00 ET
|
Erasca, Inc.
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initial SEACRAFT-1 Phase 1b combination data in RAS Q61X solid tumors expected...
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
December 11, 2023 08:00 ET
|
Erasca, Inc.
First-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors Naporafenib has been dosed in more than 500 patients to date, establishing its...
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
November 28, 2023 08:00 ET
|
Erasca, Inc.
Gained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design for naporafenib plus trametinib in NRAS mutant melanoma; initiation on track for H1 2024 Completed dose...
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
November 09, 2023 16:01 ET
|
Erasca, Inc.
First patient dosed in SEACRAFT-1 Phase 1b trial evaluating naporafenib plus trametinib Multiple upcoming catalysts across ongoing clinical programs Strong balance sheet with cash, cash equivalents,...
Erasca to Present at Upcoming Investor Conferences in November
November 08, 2023 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca to Present at the Cantor Global Healthcare Conference
September 19, 2023 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...
Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 05, 2023 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...
Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors
August 29, 2023 08:00 ET
|
Erasca, Inc.
Anti-tumor activity in patients with NRAS Q61X melanoma and KRAS Q61X NSCLC supports tissue agnostic development in RAS Q61X solid tumors Initial Phase 1b combination data from SEACRAFT-1 expected in...